[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Assembly Biosciences (ASMB)

Assembly Biosciences (ASMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 721,187
  • Shares Outstanding, K 20,361
  • Annual Sales, $ 72,300 K
  • Annual Income, $ -6,120 K
  • EBIT $ -9 M
  • EBITDA $ -11 M
  • 60-Month Beta 1.10
  • Price/Sales 9.95
  • Price/Cash Flow N/A
  • Price/Book 1.84

Options Overview Details

View History
  • Implied Volatility 60.32% (+60.32%)
  • Historical Volatility 64.97%
  • IV Percentile 1%
  • IV Rank 0.00%
  • IV High 165.07% on 09/17/25
  • IV Low 60.32% on 08/27/26
  • Expected Move (DTE 22) 0.00 (0.00%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 53
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 846
  • Open Int (30-Day) 1,092
  • Expected Range 34.80 to 34.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.44
  • Number of Estimates 1
  • High Estimate $-0.44
  • Low Estimate $-0.44
  • Prior Year $-0.72
  • Growth Rate Est. (year over year) +38.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.50 +42.04%
on 07/29/26
37.00 -5.95%
on 08/25/26
+8.89 (+34.31%)
since 07/27/26
3-Month
21.80 +59.67%
on 06/11/26
37.00 -5.95%
on 08/25/26
+7.40 (+27.01%)
since 05/27/26
52-Week
20.23 +72.02%
on 09/17/25
39.71 -12.35%
on 11/20/25
+8.91 (+34.41%)
since 08/27/25

Most Recent Stories

More News
Assembly Biosciences: Q2 Earnings Snapshot

Assembly Biosciences: Q2 Earnings Snapshot

ASMB : 34.80 (-1.75%)
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates

– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) –

ASMB : 34.80 (-1.75%)
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates

– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – – Completed $115 million gross...

ASMB : 34.80 (-1.75%)
Assembly Biosciences Nears Its Moment of Truth on the Gilead Opt-In Decision

Barchart Research What to Expect from ASMB Earnings ASMB Generated August 11, 2026 Current Price $27.27 EPS Estimate $$-0.70 Consensus Rating Strong Buy Average Move 4.34% Assembly Biosciences Nears Its...

ASMB : 34.80 (-1.75%)
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead

Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming decisions...

ASMB : 34.80 (-1.75%)
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands

Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications,...

ASMB : 34.80 (-1.75%)
Assembly Biosciences Announces Upcoming Investor Conference Presentations

SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases,...

ASMB : 34.80 (-1.75%)
Assembly Biosciences Announces Upcoming Investor Conference Presentations

SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative...

ASMB : 34.80 (-1.75%)
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases,...

ASMB : 34.80 (-1.75%)
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases,...

ASMB : 34.80 (-1.75%)

Business Summary

Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for...

See More

Key Turning Points

3rd Resistance Point 36.70
2nd Resistance Point 36.30
1st Resistance Point 35.55
Last Price 34.80
1st Support Level 34.40
2nd Support Level 34.00
3rd Support Level 33.25

See More

52-Week High 39.71
Last Price 34.80
Fibonacci 61.8% 32.27
Fibonacci 50% 29.97
Fibonacci 38.2% 27.67
52-Week Low 20.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.